Pick-up anti-oncology giant - Roche Pharmaceuticals' performance in China

Pharmaceutical Network January 19 - In the past 30 years, China's pharmaceutical market has been booming, with average sales revenue increasing by more than 17%, far higher than the global pharmaceutical market average growth rate of 8%-10%Therefore, Chinese mainland has become the preferred market for foreign pharmaceutical companies to expand their businessSo can these multinational drug companies maintain their strengths as always? Here's an analysis of Roche Pharmaceuticals, the anti-cancer giant, to see how his family is doing in the domestic marketRoche Pharmaceuticals was founded in 1896 and entered China in 1926The scope of business mainly involves drugs, medical diagnosis, vitamins and fine chemicals, fragrances and spices and other four areasAmong them, in the field of drug treatment, it involvesof central nervous system
diseases, metabolic disorders, anti-infection, antiviral, anti-
tumor, transplantation, hepatitisIts core area is anti-tumor, and it also has a large market in the field of anti-infection and immunomodulationRoche Pharmaceuticals ranked third among pharmaceutical companies in 2015 with sales of $38.791 billion, according to the 2016 Global 100 Mandatory PharmaceuticalRankings by Informa Pharma Intelligence, According to CmH, Roche is 16th in the Chinese mainland with a 1.00% market shareRoche's market share declined in the Chinese market in 2013-2015 and is expected to pick up in 2016Roche's 2013-2016 Market Share Change (Chinese mainland)Data Source: Zhongkang CMH Heavy Product Analysis FirstWordPharma's 2015 Global Brand Drug Sales Top100 reached $265 billion (Prescription Drugs), of which Roche has 8 products (litus)) Anti-beval beads single resistance, quto beads single resistance, thunder ball mono-resistance, patobean single resistance, tobed single resistance, Omaju mono-resistance, nilotini tablets) into the top 100 list, a total of $28 billion, accounting for 10.57 percent of the share , the CMH data show that in the domestic 2015 top 100, Roche only three products shortlisted, namely, caperitapentine tablets, cortisol capsules, polyethyl interferon alpha-2a injections, respectively, in the 42nd, 58th, 76th, from 2013 to 2015, the market share of these three products did not change much from CMH data, Roche into the global top100 brand products are not shortlisted for China's domestic top100 On the one hand, because some products are not on the domestic market, on the other hand, because the high price makes the use of related products limited, in addition, the competition for generic drugs will also squeeze the market of the original medicine, and access to the domestic health insurance catalog and other reasons will affect its sales For example, Roche sales of the first three products of rituxiximono resistance, beva pearl mono-resistance, quto-bea mono-resistance, only ritoxian resistance (into Heilongjiang, Jiangxi, Shandong, Qinghai, Ningxia, Guangxi, Tibet, Gansu, Guizhou) and Quto-Zhu mono-resistance (into Guangxi) into the provincial health insurance directory Source: Zhongkang CMH litusxima lituxixic itist (product name: Mera), approved by the FDA in 1997 in the United States, is the world's first approved for clinical treatment of non-Hodgkin lymphoma (NHL) monoclonal antibody, approved in 2000 in China Roche's annual report shows annual sales of more than $6.5 billion in 2011-2015, $7.327 billion in 2015 and $5.522 billion in the first three quarters of 2016 According to Zhongkang CMH data, the drug's domestic sales in 2015 was about 1.6 billion yuan domestic enterprises only Zhengda Tianqing, Hualan gene declaration of the new drug, respectively, in September and November this year approved to enter the clinical bevazumab bevazumab (commodity name: Anvitin) is a recombinant humanized monoclonal antibody that inhibits endothelial growth factors in the blood vessels used to treat various types of metastatic cancers, and was approved by the FDA on February 26, 2004, the first drug approved to be listed in the United States to inhibit tumor vascular production In 2015, the CFDA approved its first-line treatment for advanced, metastatic, or recurrent non-squamous non-squamous lung cancer Roche's report shows annual sales of more than $5.7 billion in 2011-2015, reaching $6.951 billion in 2015 and $5.15 billion in the first three quarters of 2016, making it another of Roche's top cancer products According to Zhongkang CMH data, the drug's domestic sales in 2015 was about 400 million yuan the current domestic Hengrui and Zhengda Tianqing registered to declare the new drug, have been approved into the clinical qutobeu mono-anti-
quto-bead monoantigen (commodity name: Hercetin), is anti-HER2 monoclonal antibody, approved in the United States in 1998 for breast cancer treatment, became the first targeted HER2 humanized monoclonal antibody drug, in 2010, the FDA approved its use for HER2-positive stomach cancer or gastroesophageal cancer; Roche's report shows annual sales of more than $5.7 billion in 2011-2015, reaching $6.799 billion in 2015 and $5.161 billion in the first three quarters of 2016, making it Roche's third-best-selling cancer product According to Zhongkang CMH data, the drug's domestic sales in 2015 was about 1.6 billion yuan domestic enterprises have Zhengda Tianqing and Hualan gene declaration registration of the new drug, this year were approved to enter the clinical Thunderball mono-anti-
thunder-ball mono-resistance (commodity name: Lucentis/Noxeda) is an angiogenesis inhibitor developed by Roche and Novartis (Roche has the commercial rights to the drug in the United States, Novartis has exclusive rights to the drug outside the United States), first obtained FDA approval in 2006 to treat wet age-related macular degeneration, and then increased retinal blockage caused by macular degeneration In 2010, the drug was approved by the FDA for the treatment of diabetic macular edema Roche reported sales of $1,581 million in 2015 and $2.468 billion in the first three quarters of 2016 (Roche/Novartis) According to Zhongkang CMH data, the drug's domestic sales in 2015 was about 20 million yuan (Novartis Sales) Patozumab Patozumab (product name: Perjeta) was the first monoclonal antibody called "HER dipoly inhibitors." By binding to HER2, her2 is blocked from the hybrid fusion of other HER receptors, thus slowing the growth of the tumor It was certified by the U.S FDA on June 8, 2012 to treat HER2-positive metastatic breast cancer, which was launched in Europe and Japan in 2013 and is not yet available in China The drug only $60 0.6 billion in its first year on the market, followed by rapid global sales, reaching $1.503 billion in 2015 and $1.354 billion in the first three quarters of 2016, according to Roche's annual report tobead mono-anti-
-pearl monoantigen (product name: Yamelo) is the world's first human-derived monoclonal antibody for IL-6 receptors, listed in Japan in 2005 and fda approved in the United States on January 8, 2010 Roche's annual report shows that the drug reached $1,489 million in 2015 and $1.319 billion in the first three quarters of 2016 Zhongkang CMH data show that the domestic sales in 2015 about 20 million yuan Omaju monoantidon anti-
Omaju monoantigen (commodity name: Sorrell/Xolair) is the first biological agent to treat chronic isotype urticaria, and the first drug approved for the treatment of chronic isotic urticaria after non-sedative H1-antihistamine Omaju monostya was first approved for the treatment of moderate to severe asthma in 2003 and was approved for a new adaptation certificate for chronic isotic urticaria on March 21, 2014 Roche's annual report showed sales of the drug were $1.328 billion in 2015 and $1.16 billion in the first three quarters of 2016 Elotini Elotini (trade name: Trotini) belongs to the tyrosine kinase inhibitor, which inhibits tumor growth by inhibiting the activity of tyrosine kinase, and the single drug is suitable for at least one late-stage or metastasized non-small cell lung cancer that failed a chemotherapy regimen In 2004, the FDA approved treatment for non-small cell lung cancer, advanced pancreatic cancer (in conjunction with Gissytabine), and was subsequently marketed in Europe and China for treatment of non-small cell lung cancer in 2005 and China, respectively Roche's annual report showed sales of $1.228 billion in 2015 According to Zhongkang CMH data, the drug's domestic sales in 2015 was about 900 million yuan strong new drug development capabilities
from November 2015 to November 2016, Roche launched five new drugs: melanoma drug Cobimetinib, lung cancer drug Alecensa , leukemia The drug Venetoclax, as well as the PD-L1 inhibitor Tecentriq (atezolizumab) for bladder cancer and non-small cell lung cancer, and the multiple sclerosis drug Ocrezumab (the results awaiting) Roche reported strong market momentum in the third quarter of this year, with Tecentriq (listed in 2016.18) showing strong market momentum, while EvaluatePharma, an internationally renowned drug market research firm, forecast sales of $2.5 billion in 2020, while Alecensa Q3 had sales of 122 million Swiss francs and Cotellic was 0.3billion Swiss francs show that Roche Pharmaceuticals has demonstrated strong new drug development capabilities, as an anti-tumor giant, as always, the top of the list